Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth ...
Stockhead on MSN
Astral shines as thick, high-grade gold hits from infill drilling raises confidence in Theia resource
Infill drilling at Astral Resources’ flagship Theia deposit, part of the Mandilla gold project near Kalgoorlie, is continuing ...
"The scale at which China has managed to transition so far is testament to its unwavering commitment to the technologies of ...
Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
The South African on MSN
Matric exams 2025: Here’s what will be written on Day 1
As the 2025 matric exams officially begin this week, learners are entering one of the most important periods of their school ...
Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with ...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in ...
The loan guarantee will backstop $1.6 billion for AEP, one of the nation's largest utilities, as it seeks to modernize a ...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...
(Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus placebo in patients with previously treated advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback